Most commercially available enzyme-linked immunosorbent assays incorporate a polyclonal E. coli O157:H7 antibody instead of a monoclonal alternative, perhaps because of the ease and low cost of preparation of the polyclonal antibody, the inability of the monoclonal antibody to achieve a significant increase in specificity, and the retention of greater sensitivity with the polyclonal antibody.